Faculty Information - KOBARI Yuuki

■ Published papers

1.	Other	Effectiveness and safety of enfortumab vedotin plus pembrolizumab for patients aged 80 years and older with metastatic urothelial carcinoma: A multicenter retrospective study. 2026/08
2.	Original article	Living-donor kidney transplantation after resection of mixed epithelial and stromal tumor: A positive outcome despite not observing the recommended waiting period. 2026/07
3.	Case report	Robot-assisted complete urinary tract exenteration for multifocal urothelial carcinoma: Perioperative management in non-dialysis patients 2026/07
4.	Case report	Belzutifan for metastatic TFE3-Rearranged renal cell carcinoma with pulmonary metastases: A Case Report. 2026/05/28
5.	Other	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
6.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
7.	Original article	Pathologic complete response after enfortumab vedotin plus pembrolizumab in node-positive upper tract urothelial carcinoma. 2026/05
8.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
9.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
10.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
11.	Case report	Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: Case report 2025/09/01
12.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
13.	Case report	Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases. 2025/08
14.	Other	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
15.	Other	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. 2025/05
16.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
17.	Original article	Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study. 2025/03
18.	Original article	Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
19.	Original article	Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
20.	Case report	Effectiveness of robot-assisted adrenalectomy for a giant adrenal hemangioma: A case report. 2024/09
21.	Original article	Comparison of surgical outcomes of robot‑assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single‑layer and double‑layer renorrhaphy. 2024/07/27
22.	Original article	Robot-assisted partial nephrectomy with selective artery clamping for renal cell carcinoma in horseshoe kidney. 2024/07
23.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
24.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
25.	Original article	Safety of docetaxel in a patient with metastatic castration-resistant prostate cancer after kidney transplantation: A case report. 2024/04
26.	Original article	Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
27.	Case report	Advanced renal cell carcinoma with Inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. 2024/03
28.	Original article	Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
29.	Original article	Clinical course of candidate renal tansplant recipients diagnosed with prostate cancer during pre-transplant screening test. 2024/01
30.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
31.	Case report	Long-time survival of a renal transplant recipient with metastatic mucinous tubular and spindle cell carcinoma: A case report. 2023/05
32.	Original article	Efficacy of combined pembrolizumab and pelvic radiotherapy for bladder cancer with rectal metastases. 2023/03
33.	Original article	Analyses of operative time according to procedure phases during robot-assisted laparoscopic partial nephrectomy using the iPhone application “My Intuitives” 2022/11
34.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
35.	Original article	Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma. 2021/11
36.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
37.	Original article	Comparison of postoperative recovery after robot-assisted partialnephrectomy of T1 renal tumors through retroperitoneal ortransperitoneal approach: A Japanese single institutional analysis. 2021/02
38.	Original article	Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. 2017/07
Display 5 items
Display all(38)

■ Academic conference presentation

1.	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice，General） 2026/05/18
2.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
3.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （Poster notice，General） 2026/05/16
4.	Real world data of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma: Multi-center retrospective study in Japan. （Speech，General） 2026/04/24
5.	Real-world experience with adjuvant pembrolizumab toxicities in renal cell carcinoma: A single-center experience at Tokyo Women's Medical University. （Speech，General） 2026/04/24
6.	Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
7.	Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma. （Poster notice，General） 2026/02/28
8.	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. （Poster notice，General） 2025/04/29
9.	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. （Poster notice，General） 2025/04/26
10.	Clinical outcomes of repeat robot-assisted partial nephrectomy compared to repeat open partial nephrectomy. （Speech，General） 2025/03/23
11.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
12.	Clinical course of candidate renal transplant recipients diagnosed with prostate cancer during pre-transplant screening test. （Poster notice，General） 2024/04/27
13.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
14.	BRCA mutation-positive prostate cancer at our hospital initial experience with olaparib in BRCA mutation-positive prostate cancer. （Poster notice，General） 2024/04/26
15.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
16.	Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. （Poster notice，General） 2024/04/26
17.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. （Poster notice，General） 2024/04/26
18.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. （Poster notice） 2024/04/25
19.	Comparison of surgical outcomes between robot-assisted and conventional laparoscopic adrenalectomy at Tokyo Women's Medical University Hospital. （Poster notice，General） 2024/04/25
20.	Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorraphy: Analyses of an experienced surgeon. （Speech，General） 2024/04/08
21.	Follow-up survey of candidate renal transplant recipients with prostate cancer diagnosed during the pre-transplant screening test. （Poster notice，General） 2023/08/25
22.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
23.	Initial experiences of robot-assisted adrenalectomy. （Poster notice，General） 2023/04/22
24.	Medication states of up-front ARAT treatment for mHSPC in real-world practice. （Poster notice，General） 2023/04/21
25.	Circulation kinetics analysis using computed tomography of papillary renal cell carcinoma, chromophobe renal cell carcinoma, oncocytoma, and angiomyolipoma. （Poster notice） 2023/04/20
26.	Retzius-sparing robot-assisted radical prostatectomy in a renal transplant recipient. （Poster notice，General） 2021/07/25
27.	The evaluation of living-related kidney transplantation donors in autosomal-dominant polycystic kidney disease. （Poster notice，General） 2021/06/04
28.	Retroperitoneal approach is better quality of recovery than transperitoneal approach after robot-assisted partial nephrectomy. （Poster notice，General） 2020/12/22
29.	Clinical future of mucinous tubular and spindle cell carcinoma of the kidney. （Poster notice，General） 2019/08/17
Display 5 items
Display all(29)

■ Social activities

1.

2026/06

Urology-Frontier expert seminar

■ Career achievements

● Special note of person who has experience of business
1.	2026/07/06～2026/07/17	International Visiting Scholars Training Program at Asan Medical Center, Seoul, Korea

■ Awards & honors

1.

2025

Annals of Laparoscopic and Endoscopic Surgery Annals of Laparoscopic and Endoscopic Surgery Reviewer of the Month (2025)

■ Academic society memberships

1.	2014/04	The Japanese Urological Association
2.	2025/02～	American Urological Association
3.	2014/04～	Japan Society of Clinical Oncology
4.	2014/04～	Japanese Society of Endourology and Robotics
5.	2014/04～	The Japanese Society for Dialysis Therapy

■ Education

1.	2021/12/17 Degree Acquisition	Tokyo Women's Medical University,
2.	2006/04～2012/03	Faculty of Medicine, Tokyo Medical University, Graduated

■ Academic & professional experience

1.	2026/07～2026/07	Asan Medical Center, Seoul, Korea Department of Urology
2.	2024/04～	Tokyo Women's Medical University Assistant Professor
3.	2023/04～	Tokyo Women's Medical Univercity Urology

■ Rsearch funding number

00937120

■ External Researcher ID

orcID

0000000214072588